dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pai, Sara I. |
dc.contributor.author | Cohen, Ezra E. W. |
dc.contributor.author | Lin, Derrick |
dc.contributor.author | Fountzilas, George |
dc.contributor.author | Kim, Edward S. |
dc.contributor.author | Mehlhorn, Holger |
dc.contributor.author | Basté Rotllan, Neus |
dc.date.accessioned | 2021-04-19T13:34:55Z |
dc.date.available | 2021-04-19T13:34:55Z |
dc.date.issued | 2019-12-26 |
dc.identifier.citation | Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, et al. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 Dec 26;17(1):429. |
dc.identifier.issn | 1479-5876 |
dc.identifier.uri | https://hdl.handle.net/11351/5875 |
dc.description | Biomarker; Head and neck squamous cell carcinoma; PD-L1 |
dc.description.abstract | Background
Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is controversial. This study investigates whether tumoral expression of PD-L1 is a prognostic marker in patients with recurrent and/or metastatic (R/M) HNSCC treated with standard chemotherapy.
Methods
This retrospective, multicenter, noninterventional study assessed PD-L1 expression on archival R/M HNSCC tissue samples using the VENTANA PD-L1 (SP263) Assay. PD-L1 high was defined as PD-L1 staining of ≥ 25% TC, with exploratory scoring at TC ≥ 10% and TC ≥ 50%. The primary objective of this study was to estimate the prognostic value of PD-L1 status in terms of overall survival (OS) in patients with R/M HNSCC.
Results
412 patients (median age, 62.0 years; 79.9% male; 88.2% Caucasian) were included from 19 sites in seven countries. 132 patients (32.0%) had TC ≥ 25% PD-L1 expression; 199 patients (48.3%) and 85 patients (20.6%) had TC ≥ 10% and ≥ 50%, respectively. OS did not differ significantly across PD-L1 expression (at TC ≥ 25% cutoff median OS: 8.2 months vs TC < 25%, 10.1 months, P = 0.55) or the ≥ 10% and ≥ 50% cutoffs (at TC ≥ 10%, median OS: 9.6 months vs TC < 10%, 9.4 months, P = 0.32, and at TC ≥ 50%, median OS 7.9 vs TC < 50%, 10.0 months, P = 0.39, respectively).
Conclusions
PD-L1 expression, assessed using the VENTANA PD-L1 (SP263) Assay, was not prognostic of OS in patients with R/M HNSCC treated with standard of care chemotherapies. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Journal of Translational Medicine;17(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Prognosi |
dc.subject | Cap - Càncer |
dc.subject | Coll - Càncer |
dc.subject.mesh | Squamous Cell Carcinoma of Head and Neck |
dc.subject.mesh | Prognosis |
dc.title | SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12967-019-02182-1 |
dc.subject.decs | carcinoma de células escamosas de cabeza y cuello |
dc.subject.decs | pronóstico |
dc.relation.publishversion | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02182-1 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pai SI] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. [Cohen EEW] UC San Diego Health System, Moores Cancer Center, La Jolla, CA, USA. [Lin D] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. Massachusetts Eye and Ear, Boston, MA, USA. [Fountzilas G] Aristotle University of Thessaloniki, Thessaloniki, Greece. [Kim ES] Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. [Mehlhorn H] Universitaet sklinikum Leipzig, Klinik und Poliklinik fur HNO-Heilkunde, Leipzig, Germany. [Baste N] Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31878938 |
dc.identifier.wos | 000513524800002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |